Business Wire

Mavenir Announces Industry’s Most Advanced Network Security and Fraud Management Suite

Del

Mavenir, focused on transforming mobile network economics for Communications Service Providers (CSPs), today announced its Network Security and Fraud Management Suite including a Fraud Management System equipped with big data analytics and advanced AI techniques such as machine learning and deep learning.

As operators continue to roll out new LTE-based services, Diameter signaling has become a new target for malicious attacks. Location tracking, interception of voice and text messages, denial of service on network and subscriber level, and other unauthorized activities are all potential use cases leading to fraudulent outcome that have occurred in the past with the SS7 protocol targeting 2G / 3G networks, and are also applicable to 4G networks, according to a recent report from the FCC’s Communications Security, Reliability and Interoperability Council (CSRIC).

Where security is compromised, fraud is inevitable. Traditional systems can no longer keep pace with the volume and velocity of criminal activity. Many existing systems can’t uncover new fraud types; they overwhelm the user with false positives or use dated rules that only uncover fraud long after it has taken place. Furthermore, the most impacting types and methods of fraud are related to subscription fraud, PBX hacking, international revenue share fraud, interconnect bypass, premium rate service.

Mavenir’s Security and Fraud Management Suite protects the network in real-time, and with predictive analytics and machine learning, the network is protected even as new vulnerabilities arise. Mavenir distinguishes between three main verticals within the fraud and security domain while providing the following corresponding solutions:

  • Messaging Revenue Assurance: Protects the CSPs’ revenue leakage based on innovative bypass techniques for A2P traffic. It offers efficient real-time detection of SPAM campaigns acknowledged by CSPs around the globe.
  • Network Signaling Security: Provides Signaling Firewalling solutions that implement the GSMA mitigation recommendations (FS.11 and FS.19) to detect and prevent the signaling-based attacks from happening.
  • Fraud Management: A modern data approach to fight fraud in real time. As part of its Security and Fraud Management Suite, Mavenir provides the Fraud Management Solution based on Big Data approach suited to manage the volume, velocity, and variety of structured and unstructured data over wireless networks. It relies on a unique, real-time fraud analytics platform, tailored for CSPs’ most pressing needs.

The key features of Mavenir’s Network Security and Fraud Management Suite include:

  • Easy-to-use / intuitive management interface for minimal response times to act on any unforeseen ongoing suspicious activity detected through sophisticated mitigation algorithms.
  • Powerful correlation engine offers detection of anomalous traffic patterns through efficient traffic profiling capabilities. The machine learning mechanisms behind the correlation engine create challenging obstacles for fraudulent activities to pass through unnoticed.
  • Supporting Analytics component enables CSPs to create interactive dashboards based on any required key performance indicators. The generated reports offer insights on the signaling traffic beyond security context helping the operators reveal any possible network optimizations or revise their interworking agreements.

“Malicious attacks are evolving with technology at a rapid pace and take revenue from operators. As a recent CFCA survey1 shows, global fraud levels translate into $29.2 billion global revenue loss for CSPs. Without sophisticated, adaptable, and self-learning security solutions, operators will forever be behind the technology curve with unprotected revenues,” said Pardeep Kohli, President and CEO of Mavenir. “We provide advanced cloud-native security for every type of messaging and signaling protocol used in the Telecom environment with anti-spam, anti-fraud solutions and firewall products.”

Mavenir’s cloud-native Security Suite includes Messaging (SMS, MMS, and RCS) Spam and Fraud control, Equipment Identity Register (EIR), Signaling Firewall (Diameter, SIP, SS7 and GTP), Session Border Controller (vSBC) and Mobile Edge Gateway (including ePDG, SeGW, and HeNB-GW) enabling operators to understand, monitor, enforce and maintain network security. The security suite fully covers protection of the core mobile network including the messaging revenue of modern CSPs.

Mavenir’s AI Center of Excellence is based in Brno, Czech Republic.

Visit Mavenir at 5G World in London from June 12th – 14th, 2018.

About Mavenir:

Mavenir is purpose-built to redefine mobile network economics for Communication Service Providers (CSPs). Our innovative solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and Cloud RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation and revenue protection. Learn more at mavenir.com.

 
Mavenir, the M logo, and Cloud Range are trademarks owned by Mavenir Systems, Inc.
Copyright © 2017 Mavenir Systems, Inc. All Rights Reserved.
 

 

1   CFCA Global Fraud Loss Survey for 2017

Contact information

Mavenir
Maryvonne Tubb
PR@mavenir.com
or
MatterNow
Lydia Fakhouri
mavenir@matternow.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i